“Antibiotics of the Future” – Wall Street Journal, 16 December 2013

Misuse of antibiotics in people and livestock is rampant, and has caused the formation of antibiotic-resistant germs to speed up. As a result, scientists are trying to create new antibiotics that will fight the germs that existing antibiotics can’t fight.

Scientists are using varying methods to develop new antibiotics, such as adding silver, which can increase the antibiotics’ ability to combat germs. Researchers are also employing the bacteria’s own genetic sequencing to accelerate the creation of more powerful drugs.

In the US, almost two million people are infected yearly by antibiotic-resistant bacteria, resulting in thousands of deaths. It’s natural for antibiotics to become less efficient over time: bacteria develops a resistance, which means new antibiotics need to be created regularly. Both misuse of antibiotics and a decline in antibiotic development since 1990 have added fuel to the fire.

Researchers now have the capability to develop new antibiotics by studying germs’ genomes and looking for certain gene patterns. Most antibiotics are cultivated from the bacteria’s toxins—analyzing a germs’ genes has proven to be a great, albeit slow, method to creating new antibiotics.

Researchers are also looking for ways to render germs powerless. A person becomes infected when the bacteria’s population grows to a certain amount; scientists are trying to figure out if there’s a way to break communication between the individual microbes. In addition, scientists are trying to subdue toxins and other signaling molecules that are fundamental for an infection to advance.

February 28, 2014

Fluid Management Systems

Copyright 2014   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar

“Meat Industry Won’t Fight Antibiotics Rule” – Wall Street Journal, 12 December 2013

Last week, the FDA introduced new policy that aims to curtail growth promotion antibiotics used on livestock. The use of these antibiotics on animals has been linked to the generation of antibiotic-resistant bacteria in humans.

While farmers and the meat industry support the FDA, neither think the new regulations will have an impact on the livestock industry. The FDA’s regulations deem it illegal to use antibiotics for growth promotion purposes, only allowing for antibiotic use when medically necessary. While the FDA now requires veterinarians to supervise antibiotic use on livestock, farmers will still be able to use antibiotics for preventative measures, especially in feed and water.

According to the FDA, almost 30 million pounds of antibiotics were used on livestock in 2011, a 2% increase from 2010. In 2011, around 7.3 million pounds of antibiotics were used to medicate people.

The FDA’s new policy is not mandatory for drug companies, yet animal drug companies like Zoetis and Elanco have complied. The guidelines request that drug companies remove any wording from their labels that implies that a drug promotes growth.

These are the steps in the right direction to protect animal and human health while enhancing public image for livestock and drug companies.

December 27, 2013

Fluid Management Systems

Copyright 2013   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar

“Drug Makers’ Push into Injectables Could Ease Shortages” – Wall Street Journal, 26 March 2013

Healthcare and drug companies are looking to join a market largely held by hospitals: injectable drugs, a $7 billion industry that often experiences shortages.

Drug mogul Becton Dickinson (BD), for example, plans on introducing 20-30 new injectable medicines to the US over the next few years, some of which have been in short supply. International drug companies are also seizing the market. Jordan-based Hikma Pharmaceuticals will launch 5-10 products in the next few years, also introducing a few of which have been scarce.

Companies like BD are attracted to this market because of the supply issue; and while sterilizing injectable drugs can prove difficult, the payoff is big: almost one billion vials  are sold each year. However, companies might have to wait for the long-run, as producing sterile medicines can be expensive with low profits. Many companies left the market due to the cost, leaving some drugs to just one manufacturer. In addition, manufacturing problems, supply constraints and government investigation of manufacturing plants have pushed many drug firms to abandon facilities or slow down production.

What resulted was an even larger shortage in 2011: 183, as opposed to 23 five years earlier. According to the FDA, the shortages fell to 84 in 2012, partly because Pfizer began manufacturing limited cancer injectables and some plants, which were previously shut down, reopened.

Yet, in order to turn a profit, many companies are looking into raising prices by 10%. This would greatly affect hospitals and their drug buyers, who will most likely fight the increases. In order to cut costs and availability, drug companies should consider  producing and selling drugs in multi-dose vials. Fluid Management Systems, Inc. has the technology to manage and monitor injectable drug inventories in multi-dose vials.

Conceived, Developed and Written by Dr. Subodh Das and Tara Mahadevan

April 10, 2013

Fluid Management Systems

Copyright 2013   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar